Regular moisturizing with over-the-counter (OTC) treatments is considered a cornerstone of atopic dermatitis (AD) management regardless of disease severity, but OTC moisturizers are not an eligible product under most state Medicaid benefits, including those of New York (NY). Removing the financial barrier to AD management may lessen both the economic burden and emotional toll of the disease for patients and their families with the added benefit of decreasing healthcare costs. Herein, the theoretical annual cost of OTC moisturizer was calculated for a patient with AD in NY to range between $35.13 to $63.35 for infants to $175.66 to $316.75 for adults, and Medicaid reimbursement rates and reported direct and indirect costs of AD were reviewed. We conclude with a discussion of Medicaid coverage criteria for drugs, cost-effectiveness and preventative medicine, and the role of advocacy for changes in health policy.

中文翻译：

---

非处方保湿剂的国家医疗补助覆盖范围：特应性皮炎的成本效益管理策略？

无论疾病严重程度如何，使用非处方 (OTC) 治疗进行定期保湿被认为是特应性皮炎 (AD) 管理的基石，但 OTC 保湿剂不是大多数州医疗补助计划的合格产品，包括纽约 (NY) 的那些. 消除 AD 管理的财务障碍可能会减轻患者及其家人的经济负担和情感损失，同时降低医疗保健成本。在此，计算了纽约一名 AD 患者的 OTC 保湿剂理论年费用，范围为婴儿 35.13 美元至 63.35 美元至成人 175.66 美元至 316.75 美元，并对医疗补助报销率和报告的 AD 直接和间接费用进行了审查。最后，我们讨论了药物的 Medicaid 覆盖标准，